Infinity Reports Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 Across a Broad Range of Blood Cancers at the 12th International Conference on Malignant Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. announced encouraging Phase 1 data from an ongoing study of IPI-145, a potent PI3K-delta and PI3K-gamma inhibitor, in patients with potentially fatal blood cancers.

Source: http://feeds.businesswire.com/click.phdo?i=1a91829ccd90f9383dd2b5dde9e8cd17

Pop Up Trade Show Displays Pop Up Displays